<- Go Home
Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Market Cap
$40.2M
Volume
27.0K
Cash and Equivalents
$19.0M
EBITDA
-$19.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.1M
Profit Margin
100.00%
52 Week High
$4.89
52 Week Low
$1.81
Dividend
N/A
Price / Book Value
2.30
Price / Earnings
-2.15
Price / Tangible Book Value
2.32
Enterprise Value
$21.0M
Enterprise Value / EBITDA
-1.05
Operating Income
-$20.1M
Return on Equity
72.17%
Return on Assets
-41.86
Cash and Short Term Investments
$19.0M
Debt
N/A
Equity
$17.1M
Revenue
$1.1M
Unlevered FCF
-$11.5M
Sector
Biotechnology
Category
N/A